The US approach to biosimilars explained

February 15, 2012

The FDA’s draft guidance for biosimilars has provided some clarity for biosimilar applicants and innovator biologic companies. But lawyers say many questions remain

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login

Varuni Paranavitane, of counsel at Finnegan, examines recent decisions by US and UK courts to demonstrate the proof of infringement that was required

Varuni Paranavitane, June 06, 2023

The Federal Circuit will also narrow its investigation into Judge Newman to focus on whether her failure to cooperate constitutes misconduct

Rani Mehta, June 06, 2023

The management board will send three names to the Council of the EU for a final decision

Rory O’Neill, June 06, 2023

Sources say a decision by the IP High Court will make it easier for rights owners to fight infringement

Sukanya Sarkar, June 06, 2023

Seán Kelly asked the European Commission how it intends to ensure the EUIPO executive director vote, due tomorrow, will be fair and transparent

Rory O’Neill, June 05, 2023

Counsel from BMW and Finnegan explain how they got an NPE to sign a covenant agreeing not to sue the automaker ever again

Rani Mehta, June 02, 2023

The blue checkmark could be a good tool, but it’s unclear how widespread its adoption will be, say in-house sources

Rani Mehta, June 02, 2023

Sarah Harris, partner at Williams & Connolly, reveals how her team secured a copyright victory at SCOTUS and reflects on why the case matters

Rani Mehta, June 02, 2023

This week on MIP: UPC arrives

We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP

Rory O’Neill, June 02, 2023

A Court of Appeal judge demanded respect for solicitor-judges after reprimanding a barrister for his 'unwise' words

Rory O’Neill, June 01, 2023